During the past decade, ES-Madrid-CSGREGORIOMARANON conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "ES-Madrid-CSGREGORIOMARANON" #1 collaborator was "Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)" with 2 trials as a collaborator and "Astellas Pharma Global Development, Inc." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "ES-Madrid-CSGREGORIOMARANON" are "Acute Myeloid Leukemia" (2 trials) and "Myelodysplastic Syndrome With Excess Blasts-2" (2 trials). Many other conditions were trialed in "ES-Madrid-CSGREGORIOMARANON" in a lesser frequency.

Most popular intervention types in "ES-Madrid-CSGREGORIOMARANON" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "AG-120" (1 trials), "AG-221" (1 trials), "Gilteritinib" (1 trials), "Midostaurin" (1 trials) and "Placebo for AG-120" (1 trials). Other intervention names were less common.

The vast majority of trials in "ES-Madrid-CSGREGORIOMARANON" are 2 trials for "All" genders.

Currently, there are NaN active trials in "ES-Madrid-CSGREGORIOMARANON". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in ES-Madrid-CSGREGORIOMARANON, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in ES-Madrid-CSGREGORIOMARANON, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".